Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 5/2017

01-04-2017 | AdisInsight Report

Rucaparib: First Global Approval

Author: Yahiya Y. Syed

Published in: Drugs | Issue 5/2017

Login to get access

Abstract

Rucaparib (Rubraca™) is an oral, small molecule, poly (ADP-ribose) polymerase inhibitor being developed by Clovis Oncology, Inc. (Boulder, CO, USA) for the treatment of solid tumours. It has been approved in the USA as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. A marketing authorization application for rucaparib for the same indication has been submitted to the European Medicines Agency. Rucaparib is also under phase II or III investigation in ovarian, breast and prostate cancer. This article summarizes the milestones in the development of rucaparib leading to this first approval for ovarian cancer.
Literature
1.
2.
Jenner ZB, Sood AK, Coleman RL. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncol. 2016;12(12):1439–56.CrossRefPubMed
3.
Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75–87.CrossRefPubMed
4.
Plummer R, Lorigan P, Steven N, et al. A phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol. 2013;71(5):1191–9.CrossRefPubMed
5.
Clovis Oncology Inc. Clovis Oncology, Inc. receives license for worldwide development and commercialization rights to Pfizer’s oral and IV PARP inhibitor PF-01367338 [media release]. 2011. http://​www.​clovisoncology.​com.
6.
7.
8.
Murai J, Huang SY, Renaud A, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2014;13(2):433–43.CrossRefPubMed
9.
10.
Murray J, Thomas H, Berry P, et al. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. Br J Cancer. 2014;110(8):1977–84.CrossRefPubMedPubMedCentral
11.
Plummer R, Jones C, Middleton M, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res. 2008;14(23):7917–23.CrossRefPubMedPubMedCentral
12.
Drew Y, Ledermann J, Hall G, et al. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer. 2016;114(12):723–30.CrossRefPubMedPubMedCentral
13.
Ihnen M, Zu Eulenburg C, Kolarova T, et al. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Mol Cancer Ther. 2013;12(6):1002–15.
14.
Chuang HC, Kapuriya N, Kulp SK, et al. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat. 2012;134(2):649–59.CrossRefPubMedPubMedCentral
15.
Robillard L, Lin K, Lopez-Casas PP, et al. Preclinical efficacy of the PARP inhibitor rucaparib (CO-338/AG014699/PF-01367338) in pancreatic cancer models with homologous recombination deficiencies (HRD) [abstract no. 249]. Eur J Cancer. 2014;50(Suppl 6):83.CrossRef
16.
Drew Y, Mulligan EA, Vong W-T, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst. 2011;103(4):334–46.CrossRefPubMed
17.
Al Rubaish SS, Xiong Y, Marchion D, et al. Development of a rucaparib response signature that shows in vitro predictive value to the PARP inhibitors, ABT-888 and olaparib in ovarian cancer cells [abstract no. 54]. Gynecol Oncol. 2014;133(Suppl 1):22.CrossRef
18.
Audrey LC, Vanessa C, Marie K. The PARP inhibitor, Rucaparib enhance the sensitivity to Trabectedin in soft tissue sarcomas cell lines and in patient xenograft model [abstract no. 3002]. Cancer Res. 2016;76(Suppl 14). doi:10.​1158/​1538-7445.​AM2016-3002
19.
Falzacappa MV, Ronchini C, Faretta M, et al. The combination of the PARP inhibitor rucaparib and 5FU is an effective strategy for treating acute leukemias. Mol Cancer Ther. 2015;14(4):889–98.CrossRefPubMed
20.
Daniel RA, Rozanska AL, Mulligan EA, et al. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. Br J Cancer. 2010;103(10):1588–96.CrossRefPubMedPubMedCentral
21.
Hoch U, Charych D. Combining the long-acting topoisomerase 1-inhibitor etirinotecan pegol with the PARP inhibitor rucaparib to provide anti-tumor synergy without increased toxicity [abstract no. 33]. Eur J Cancer. 2014;50(Suppl 6):16–7.CrossRef
22.
Kotsopoulos IC, Begbie JA, Mukhopadhyay A, et al. In vitro single agent rucaparib cytotoxicity and cisplatin chemo-potentiation in cervical cancer cell lines [abstract no. IGCS-0702]. Int J Gynecol Cancer. 2016;26(Suppl 3):374.
23.
Porcelli L, Quatrale AE, Mantuano P, et al. Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Mol Oncol. 2013;7(3):308–22.CrossRefPubMed
24.
Hunter JE, Willmore E, Irving JA, et al. NF-kappaB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699. Oncogene. 2012;31(2):251–64.CrossRefPubMed
25.
Nile DL, Rae C, Hyndman IJ, et al. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma. BMC Cancer. 2016;16(1):621.CrossRefPubMedPubMedCentral
26.
Cullinane C, Waldeck K, Eu P, et al. The PARP inhibitor, rucaparib enhances the antitumor activity of 177Lu-DOTA-octreotate radionuclide therapy in preclinical models of neuroendocrine tumor [abstract no. 1800]. Cancer Res. 2015;75(Suppl 15). doi:10.​1158/​1538-7445.​AM2015-1800
27.
McCrudden CM, O’Rourke MG, Cherry KE, et al. Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself. PLoS One. 2015;10(2):e0118187.CrossRefPubMedPubMedCentral
28.
Ali M, Kamjoo M, Thomas HD, et al. The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice. Mol Cancer Ther. 2011;10(12):2320–9.CrossRefPubMedPubMedCentral
29.
Ali M, Telfer BA, McCrudden C, et al. Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? Clin Cancer Res. 2009;15(19):6106–12.CrossRefPubMedPubMedCentral
30.
McCormick A, Nakjang S, Donoghue P, et al. The role of homologous recombination recovery in cisplatin and rucaparib resistance in ovarian cancer [abstract no. ESGO-0857]. Int J Gynecol Cancer. 2015;25(Suppl 9):627.
31.
32.
Durmus S, Sparidans RW, van Esch A, et al. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699). Pharm Res. 2015;32(1):37–46.CrossRefPubMed
33.
Parrish KE, Cen L, Murray J, et al. Efficacy of PARP inhibitor rucaparib in orthotopic glioblastoma xenografts is limited by ineffective drug penetration into the central nervous system. Mol Cancer Ther. 2015;14(12):2735–43.CrossRefPubMedPubMedCentral
34.
Sun Y, Ding H, Liu X, et al. INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells. Tumour Biol. 2014;35(5):4469–77.CrossRefPubMed
35.
Kristeleit RS, Shapira-Frommer R, Oaknin A, et al. Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): analysis of pooled data from study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2) [abstract no. 856O]. In: European Society for Medical Oncology 2016 Congress. 2016.
36.
Shapira-Frommer R, Oza A, Domchek SM, et al. A phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation [abstract no. 2746 plus poster]. Eur J Cancer. 2015;51(Suppl 3):S545.CrossRef
37.
Coleman RL, Swisher EM, Oza AM, et al. Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: a phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC) [abstract no. 5540 plus poster]. J Clin Oncol. 2016;34(Suppl).
38.
Kristeleit RS, Burris HA, LoRusso P, et al. Phase 1/2 study of oral rucaparib: final phase 1 results [abstract no. 2573]. J Clin Oncol. 2014;32(Suppl 5).
39.
Miller K, Tong Y, Jones DR, et al. Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: final efficacy results of Hoosier Oncology Group BRE09-146 [abstract no. 1082]. J Clin Oncol. 2015;33(Suppl 15).
40.
Domchek SM, Hendifar AE, McWilliams RR, et al. RUCAPANC: an open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation [abstract no. 4110 plus poster]. J Clin Oncol. 2016;34(Suppl).
41.
42.
43.
Toms C, Chopra N, Houlton L, et al. Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO) [abstract no. 219TiP]. Ann Oncol. 2016;27(Suppl 6).
Metadata
Title
Rucaparib: First Global Approval
Author
Yahiya Y. Syed
Publication date
01-04-2017
Publisher
Springer International Publishing
Published in
Drugs / Issue 5/2017
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-017-0716-2

Other articles of this Issue 5/2017

Drugs 5/2017 Go to the issue

Adis Drug Evaluation

Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN®): A Review in Diabetic Macular Edema

Review Article

Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience

Review Article

The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus

Current Opinion

Therapeutic Options in Refractory Diabetic Macular Oedema

Review Article

JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects

Adis Drug Evaluation

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity